CON

Rating neutralAI MemoPost-earnings T+3

Concentra Group Parent

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 earnings beat and FY2026 guidance raise • 2026-08-06

Base target: $35 / p=50% prob

Biggest risk

The positive print is substantially reflected in the post-release price move. The accessible analyst evidence identified a July 14 Truist $37 target, which predates the Q2 release; no reliable post-print rating, target, or estimate revision was located as of August 8. The November leadership transition, approximately 2.99x net leverage, and repeated director share sales add execution and sentiment risk. [#SEC-8K-2026-08-06] [#SEC-FORM4-2026-08-05] [Benzinga analyst page](https://www.benzinga.com/quote/CON/analyst-ratings)

Invalidation

Break below $28 or thesis failure.

What would change my mind?

The Q2 print exceeded the pre-release consensus context on revenue and EPS, with strong EBITDA and free-cash-flow growth, while FY2026 guidance was raised. Continued visit growth, pricing and operating leverage could support future earnings revisions. [#SEC-8K-2026-08-06] [#PR-EARNINGS-2026-07-30]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-08

Base target

$35

p=50%

Bull target

$40

p=25%

Bear target

$28

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-print reaction and valuation digestion
Volume, pricing and operating leverage
The Q2 print exceeded the pre-release consensus context on revenue and EPS, with strong EBITDA and free-cash-flow growth, while FY2026 guidance was raised.

BearKey bullets

Director Robert Ortenzio reported repeated 130,000-share open-market sales from May through August; these are insider-activity signals, not evidence of operating weakness.
[#SEC-FORM4-2026-08-05]
Leadership changes take effect November 1, 2026, creating transition and execution risk.

WatchKey bullets

Q2 earnings beat and FY2026 guidance raise

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $35 (p=50%)

Target spread vs base: +14% / -20%

Scenario probabilities

Bull Target: $40 (p=25%)Base Target: $35 (p=50%)Bear Target: $28 (p=25%)

Commentary

The company confirmed Q2 results through its SEC filing and scheduled the August 7 earnings call through investor relations. News tone and the immediate market reaction were positive, with CON at $34.06 on August 7 and up about 11.6% from the prior close. However, no reliable post-print analyst revisions were located, so the reaction is not treated as confirmation of a durable long-term rerating. [#SEC-8K-2026-08-06] [Concentra IR](https://ir.concentra.com/) [Yahoo Finance](https://finance.yahoo.com/quote/CON/)

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-print reaction and valuation digestion
Volume, pricing and operating leverage

Scenarios

Bull Target (Scenario probability)

$40 / p=25% prob

Base Target (Scenario probability)

$35 / p=50% prob

Bear Target (Scenario probability)

$28 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.72

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-08-06
Q2 earnings beat and FY2026 guidance raise
The SEC 8-K exhibit reported Q2 revenue of $606.0 million, EPS of $0.51, adjusted EBITDA growth of 22.5%, and a FY2026 guidance increase. Pre-release Zacks context cited consensus EPS of $0.42 and revenue of $592.5 million. Concentra's investor-relations site also lists the August 7 Q2 earnings call. [#SEC-8K-2026-08-06] [#PR-EARNINGS-2026-07-30] [Concentra IR](https://ir.concentra.com/)
Prob 85.00% • Move 7.00% • Priced-in 90.00%
EVENT2026-11-01
Planned leadership transition
Matt DiCanio is scheduled to become president and CEO while Keith Newton transitions to executive chairman on November 1, 2026; the company describes the process as intended to provide leadership continuity. [#SEC-8K-2026-08-06]
Prob 65.00% • Move 2.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Post-print reaction and valuation digestion
2026-08-15
The August 7 market snapshot showed CON at $34.06, up about 11.6% from the prior close. The stored analyst-target summary shows a median of $34.625 with no reported target count, so the initial positive reaction may leave limited residual upside and room for consolidation. [Yahoo Finance](https://finance.yahoo.com/quote/CON/)
Prob 55% • Move -7% • Priced-in 60%

Long-term Catalysts

Months to a year

Volume, pricing and operating leverage
2026-12-31
Patient visits per day increased 2.6% year over year, revenue per visit increased 4.6%, and adjusted EBITDA growth exceeded revenue growth, supporting a continued operating-leverage thesis if execution persists. [#SEC-8K-2026-08-06]
Prob 65% • Move 12% • Priced-in 45%

Risks

Director Robert Ortenzio reported repeated 130,000-share open-market sales from May through August; these are insider-activity signals, not evidence of operating weakness. [#SEC-FORM4-2026-08-05]
Leadership changes take effect November 1, 2026, creating transition and execution risk.
Net leverage was reported at 2.99x after Q2, leaving sensitivity to cash-flow or growth deterioration. [#SEC-8K-2026-08-06]
Post-print analyst estimate revisions, rating changes, and target changes remain unavailable, limiting confirmation of a durable rerating.
The positive earnings reaction could reverse if future volume, pricing, margins, or guidance fail to sustain the Q2 trajectory.

Peers

Symbol	Summary
ABT	Large diversified healthcare and device comparator; useful only as a broad valuation reference because its operating mix differs materially from Concentra.
BSX	Large medical-device comparator with stronger device exposure; not a direct occupational-health operating peer.
EW	Medtech comparator with a different procedure and product model; peer relevance is limited.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

ABT

Large diversified healthcare and device comparator; useful only as a broad valuation reference because its operating mix differs materially from Concentra.

BSX

Large medical-device comparator with stronger device exposure; not a direct occupational-health operating peer.

Medtech comparator with a different procedure and product model; peer relevance is limited.